Searching News Database: SANCTURA
HSMN NewsFeed - 5 Aug 2014
TesoRx Closes $10M in Funding, Secures Key Patent and Hires Renowned Urologist as Chief Medical Officer
TesoRx Closes $10M in Funding, Secures Key Patent and Hires Renowned Urologist as Chief Medical Officer
HSMN NewsFeed - 10 Jul 2009
Bioniche Life Sciences Inc. and Endo Pharmaceuticals Sign Licensing Agreement for Urocidin(TM)
Bioniche Life Sciences Inc. and Endo Pharmaceuticals Sign Licensing Agreement for Urocidin(TM)
HSMN NewsFeed - 12 Mar 2009
FDA Accepts Complete Response Submission to New Drug Application for NEBIDO(R)
FDA Accepts Complete Response Submission to New Drug Application for NEBIDO(R)
HSMN NewsFeed - 5 Jan 2009
Indevus Pharmaceuticals Announces Definitive Merger Agreement With Endo Pharmaceuticals
Indevus Pharmaceuticals Announces Definitive Merger Agreement With Endo Pharmaceuticals
HSMN NewsFeed - 26 Sep 2008
Indevus Announces Agreement With Teva to Develop Pagoclone for the Treatment of Stuttering
Indevus Announces Agreement With Teva to Develop Pagoclone for the Treatment of Stuttering
HSMN NewsFeed - 22 May 2008
Indevus Pharmaceuticals Licenses Canadian Rights for SANCTURA XR(TM) to Allergan, Inc.
Indevus Pharmaceuticals Licenses Canadian Rights for SANCTURA XR(TM) to Allergan, Inc.
HSMN NewsFeed - 3 Mar 2008
Indevus Pharmaceuticals Announces Retirement Plans For Its CEO and Chairman
Indevus Pharmaceuticals Announces Retirement Plans For Its CEO and Chairman
HSMN NewsFeed - 17 Aug 2007
Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
HSMN NewsFeed - 29 Jun 2007
Indevus Appoints Industry Veteran Kurt Lewis as Senior Vice President Sales & Marketing
Indevus Appoints Industry Veteran Kurt Lewis as Senior Vice President Sales & Marketing
HSMN NewsFeed - 25 Jun 2007
Indevus Announces Launch of SUPPRELIN(R) LA for Central Precocious Puberty
Indevus Announces Launch of SUPPRELIN(R) LA for Central Precocious Puberty
HSMN NewsFeed - 31 May 2007
Indevus Announces Authorization for Approval of VANTAS(R) in Selected European Countries
Indevus Announces Authorization for Approval of VANTAS(R) in Selected European Countries
HSMN NewsFeed - 25 Apr 2007
Alkermes and Indevus Announce Initiation of Phase 2a Clinical Study of ALKS 27 for the Treatment of COPD
Alkermes and Indevus Announce Initiation of Phase 2a Clinical Study of ALKS 27 for the Treatment of COPD
HSMN NewsFeed - 19 Apr 2007
Indevus Announces Submission of Supplemental NDA to Reintroduce VALSTAR(R) to Treat Bladder Cancer
Indevus Announces Submission of Supplemental NDA to Reintroduce VALSTAR(R) to Treat Bladder Cancer
HSMN NewsFeed - 13 Dec 2006
FDA Accepts New Drug Application for SANCTURA XR(TM) Submitted by Indevus
FDA Accepts New Drug Application for SANCTURA XR(TM) Submitted by Indevus
HSMN NewsFeed - 5 Dec 2006
Indevus and Sanofi-Aventis' Spin-Out Company, Novexel, Announce Out-licensing of Aminocandin Anti-fungal
Indevus and Sanofi-Aventis' Spin-Out Company, Novexel, Announce Out-licensing of Aminocandin Anti-fungal
HSMN NewsFeed - 6 Nov 2006
Indevus Announces Licensing and Manufacturing Pact for SANCTURA XR(TM) With Madaus GmbH
Indevus Announces Licensing and Manufacturing Pact for SANCTURA XR(TM) With Madaus GmbH
HSMN NewsFeed - 20 Oct 2006
Indevus Announces the Finalization of Supply Agreement with Schering AG, Germany for NEBIDO(R)
Indevus Announces the Finalization of Supply Agreement with Schering AG, Germany for NEBIDO(R)
HSMN NewsFeed - 17 Oct 2006
Indevus Pharmaceuticals Announces Appointment of Thomas Farb as President and Chief Operating Officer
Indevus Pharmaceuticals Announces Appointment of Thomas Farb as President and Chief Operating Officer
HSMN NewsFeed - 7 Jul 2006
Indevus Announces Positive Data from Second Phase III Trial for SANCTURA XR(TM) in Overactive Bladder
Indevus Announces Positive Data from Second Phase III Trial for SANCTURA XR(TM) in Overactive Bladder
Additional items found! 33
Members Archive contains
33 additional stories matching:
SANCTURA
(Password required)
SANCTURA
(Password required)